Skip to content

This study aims to understand better approaches for treating anemia in patients with CKD. By doing so, it aspires to make a significant contribution to the enhancement of patient care and overall outcomes.

Anemia Management in Chronic Kidney Disease: A Comparative Evaluation of HIF-PHD Inhibitor(s) and ESAs - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061359
Enrollment
104
Registered
2024-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R718- Other abnormality of red blood cells

Interventions

Intervention1: NIL: Intervention and comparator: NIL

Sponsors

National Institute of Pharmaceutical Education and Research, Mohali
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A. All patients who are diagnosed with CKD with renal anemia & undergoing dialysis B. Patient should have been on dialysis for at least 3 months. C. Patients between 18-75 years will receive HIF-PHD inhibitors or ESAs

Exclusion criteria

Exclusion criteria: A. Inability to give informed consent B. Patients unable to complete the interview C. Psychiatric illness D. History of malignancy E. Any active or recent history of blood loss F. Taking part in other drug studies G. Pregnant and breastfeeding women

Design outcomes

Primary

MeasureTime frame
1. Change(s) in hemoglobin from baseline to 3 rd, 6th and 12th months. 2. Changes in the iron utilization parameters, including serum iron, TIBC, TSAT, ferritin, EPO level, sTfR, Hepcidin, RET-He and relevant biochemistry laboratory results from baseline. Timepoint: 1. Change(s) in hemoglobin from baseline to 3 rd, 6th and 12th months. 2. Changes in the iron utilization parameters, including serum iron, TIBC, TSAT, ferritin, EPO level, sTfR, Hepcidin, RET-He and relevant biochemistry laboratory results from baseline.

Secondary

MeasureTime frame
The secondary outcomes of the study will focus on the treatment-emergent adverse effects (TEATs) and serious adverse events, cardiovascular events, and hospitalization. The study will report adverse events during the follow-up period, with a focus on drug discontinuation due to adverse events. To determine the differences in the treatment cost among CKD patients with anemia undergoing dialysis To assess the HRQoL of dialysis CKD patients CKD-AQ (chronic kidney disease-Anemia Questionnaire) will be used for the assessment of Anemia in CKDTimepoint: 1 Year

Countries

India

Contacts

Public ContactDr. Sanjay Dcruz

Goverment Medical College and Hospital (GMCH) Chandigarh)

sanjaydcruz@gmail.com9646121556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026